Advertisement
Diabetes, Insulin Resistance and Dyslipidemia| Volume 13, ISSUE 3, e5-e6, May 2019

A Randomized Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the BERSON Clinical Trial

DOI:https://doi.org/10.1016/j.jacl.2019.04.019
A Randomized Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the BERSON Clinical Trial
Previous ArticleMarked reduction of Lipoprotein (a) with PCSK9 Inhibition in a statin intolerant patient: An Illustrative Case Report
Next ArticleEvolocumab in Patients With Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the China Population from the BERSON Clinical Trial
      Advisory board and steering committee member for and has received research grants and speaker fees from Amgen Inc.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      287

      Identification

      DOI: https://doi.org/10.1016/j.jacl.2019.04.019

      Copyright

      © 2019 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX